Ujin Pharma Ltd. has filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI) on Jun 22, 2026 for its upcoming Initial Public Offering (IPO). The company plans to offer 1.92 crore shares to the public through the IPO.
Breaking Down the Ujin Pharma IPO Details
- IPO Type: Book Built Issue
- IPO Sale Type: Fresh Issue and Offer for Sale (OFS)
- Fresh Issue: Up to 1.19 crore equity shares
- Offer for Sale (OFS): Up to 0.73 crore equity shares
- Face Value: ₹10 per equity share
- Lead Manager: SMC Capitals Ltd.
- Registrar: Kfin Technologies Ltd.
The equity shares are proposed to be listed on NSE and BSE.
Issue Reservation
According to the DRHP, the issue comprises Not more than 50% of the Net Offer for Qualified Institutional Buyers (QIBs), Not less than 15% of the Net Offer for Non-Institutional Investors and Not less than 35% of the Net Offer for Retail Individual Bidders.
About the company
Incorporated in May 2024, Ujin Pharma Limited is a chemical distribution and supply company engaged in the trading and distribution of solvents, specialty chemicals, acids, monomers, pharmaceutical raw materials, and nutraceuticals. The company serves a diverse customer base across pharmaceuticals, agrochemicals, specialty chemicals, petrochemicals, automotive, paints & coatings, printing inks, packaging, and industrial sectors.Financial Performance Highlights:
Ujin Pharma Ltd.’s total income grew by 9%, reached ₹1,636.06 crore in Mar 31, 2025, compared to ₹1,497.33 crore in Mar 31, 2024.
For the same period, profit after tax declined 10% to ₹14.29 crore, compared to ₹16.01 crore.
For the latest period ended on Dec 31, 2025, its total income stood at ₹1,523.11 crore and PAT stood at ₹25.47 crore.
